Recently, a mechanism of tumoral immune resistance centered on tryptophan degradation by TDO has been described in human tumors, such as melanoma, hepatocarcinoma, glioma and bladder carcinoma, but not in leukemia or lymphoma [13,14]. This evidence concerns the gene TDO2 and glioma.